Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty

被引:30
作者
Friedman, Richard J.
机构
[1] Charleston Orthopaed Associates, Charleston, SC USA
[2] Med Univ S Carolina, Charleston, SC 29425 USA
关键词
DEEP-VEIN THROMBOSIS; WEIGHT HEPARIN-PROPHYLAXIS; RANDOMIZED DOUBLE-BLIND; MAJOR ORTHOPEDIC-SURGERY; A-DOUBLE-BLIND; REPLACEMENT SURGERY; PROLONGED THROMBOPROPHYLAXIS; POSTOPERATIVE FONDAPARINUX; POSTTHROMBOTIC SYNDROME; RISK-ASSESSMENT;
D O I
10.5435/00124635-200703000-00004
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Elective total hip arthroplasty and total knee arthroplasty are associated with a high risk of postoperative venous thromboembolism. Traditionally, antithrombotic prophylaxis has been administered during the hospital stay. However, with patients spending less time in the hospital after surgery, there is a need to continue thromboprophylaxis beyond hospital discharge. The current recommendation for prophylaxis in total joint arthroplasty patients is a minimum of 10 days, with extended prophylaxis up to 28 to 35 days following total hip arthroplasty. Prophylaxis with low-molecular-weight heparins for approximately 4 weeks following hip arthroplasty has resulted in clinically significant reductions in the incidence of venographically confirmed deep vein thrombosis. Currently, no data support extended thromboprophylaxis beyond 10 days following total knee arthroplasty. Using weighted risk factors to assess individual risk for venous thromboembolism can help the physician determine the optimal duration of prophylaxis.
引用
收藏
页码:148 / 155
页数:8
相关论文
共 43 条
[1]  
Agnelli G., 2000, Seminars in Hematology, V37, P23, DOI 10.1016/S0037-1963(00)90097-0
[2]   Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001 - Findings from the hip and knee registry [J].
Anderson, FA ;
Hirsh, J ;
White, K ;
Fitzgerald, RH .
CHEST, 2003, 124 (06) :349S-356S
[3]  
ARCELUS JI, 1991, SEMIN THROMB HEMOST, V17, P313
[4]   Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. [J].
Bauer, KA ;
Eriksson, BI ;
Lassen, MR ;
Turpie, AGG .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (18) :1305-1310
[5]   Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement [J].
Bergqvist, D ;
Benoni, G ;
Bjorgell, O ;
Fredin, H ;
Hedlundh, U ;
Nicolas, S ;
Nilsson, P ;
Nylander, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10) :696-700
[6]  
CAPRINI JA, 1991, SEMIN THROMB HEMOST, V17, P304
[7]   Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease [J].
Caprini, JA ;
Arcelus, JI ;
Reyna, JJ .
SEMINARS IN HEMATOLOGY, 2001, 38 (02) :12-19
[8]   The influence of oral anticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement [J].
Caprini, JA ;
Arcelus, JI ;
Motykie, G ;
Kudrna, JC ;
Mokhtee, D ;
Reyna, JJ .
JOURNAL OF VASCULAR SURGERY, 1999, 30 (05) :813-820
[9]  
Cohen AT, 2000, HAEMOSTASIS, V30, P88
[10]   Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement [J].
Comp, PC ;
Spiro, TE ;
Friedman, RJ ;
Whitsett, TL ;
Johnson, GJ ;
Gardiner, GA ;
Landon, GC ;
Jové, M .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2001, 83A (03) :336-345